88 results on '"D'Onghia M"'
Search Results
2. A-348 - Dermoscopic, Reflectance Confocal Microscopy and Line-field Optical Coherence Tomography features of Cutaneous Lymphomas
- Author
-
D'onghia, M., Sanches, M., Erasti, M., Suppa, M., Tognetti, L., Rubegni, P., and Cinotti, E.
- Published
- 2024
- Full Text
- View/download PDF
3. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study
- Author
-
Paolicelli, Damiano, Manni, A., Iaffaldano, A., Di Lecce, V., D’Onghia, M., Iaffaldano, P., and Trojano, M.
- Published
- 2016
- Full Text
- View/download PDF
4. Line‐field confocal optical coherence tomography to help the diagnosis of graphite tattoo.
- Author
-
Castellano, R., D'Onghia, M., Tognetti, L., Suppa, M., Giorgino, G., Rubegni, P., and Cinotti, E.
- Subjects
- *
OPTICAL coherence tomography , *GRAPHITE , *TATTOOING , *DIAGNOSIS - Abstract
This article discusses the use of line-field confocal optical coherence tomography (LC-OCT) in diagnosing graphite tattoos. Graphite tattoos are exogenous lesions that occur when graphite from a pencil penetrates the skin or mucosa. The diagnosis of graphite tattoos is typically based on patient history and clinical examination, but LC-OCT can provide additional information by showing hyper-reflective particles in the mid dermis. This non-invasive imaging technique could be a useful tool in identifying graphite tattoos, particularly in children, and reducing the need for invasive procedures. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
5. Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment
- Author
-
Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G.B., Tortorella, C., Simone, I.L., Patti, F., Ghezzi, A., Portaccio, E., Rossi, P., Pozzilli, C., Salemi, G., Lugaresi, A., Bergamaschi, R., Millefiorini, E., Clerico, M., Lus, G., Vianello, M., Avolio, C., Cavalla, P., Iaffaldano, P., Direnzo, V., D'Onghia, M., Lepore, V., Livrea, P., Comi, G., and Amato, M.P.
- Published
- 2009
- Full Text
- View/download PDF
6. The impact of neutralizing antibodies on the risk of disease worsening in interferon β–treated relapsing multiple sclerosis: a 5 year post-marketing study
- Author
-
Paolicelli, D., D’Onghia, M., Pellegrini, F., Direnzo, V., Iaffaldano, P., Lavolpe, V., and Trojano, M.
- Published
- 2013
- Full Text
- View/download PDF
7. Letters to the Editors
- Author
-
Ciaffi, J., Giuggioli, D., Mari, A., D Onghia, M., Spinella, A., Brusi, V., Mancarella, L., Lisi, L., Faranda Cordella, J., Freeman, D., Landini, M. P., Ferri, C., Meliconi, R., and Ursini, F.
- Published
- 2021
8. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs
- Author
-
Portaccio, Emilio, Ghezzi, Angelo, Hakiki, Bahia, Sturchio, Andrea, Martinelli, Vittorio, Moiola, Lucia, Patti, Francesco, Mancardi, Gian Luigi, Solaro, Claudio, Tola, Maria Rosaria, Pozzilli, Carlo, De Giglio, Laura, Totaro, Rocco, Lugaresi, Alessandra, De Luca, Giovanna, Paolicelli, Damiano, Marrosu, Maria Giovanna, Comi, Giancarlo, Trojano, Maria, Amato, Maria Pia, Amato, MP, Portaccio, E, Hakiki, B, Sturchio, A, Pastò, L, Giannini, M, Razzolini, L, Piscolla, E, Siracusa, G, Ghezzi, A, Rizzo, A, Zaffaroni, M, Martinelli, V, Radaelli, M, Moiola, L, Comi, G, Protti, A, Spreafico, C, Marazzi, R, Cavalla, P, Masera, S, Bergamaschi, R, Mancardi, G, Capello, E, Solaro, C, Tola, MR, Caniatti, L, Granella, F, Immovilli, P, Annunziata, P, De Santi, L, Plewnia, K, Guidi, L, Bartolozzi, ML, Mazzoni, M., Pozzilli, C, De Giglio, L, Totaro, R, Carolei, A, Rossi, M, Lugaresi, A, De Luca, G., Di Tommaso, V, Trojano, M, Paolicelli, D, Carrozzo, A, DʼOnghia, M, Marrosu, MG, Musu, L, Patti, F, Carmela, L, and Lo Fermo, S
- Published
- 2014
- Full Text
- View/download PDF
9. How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial: OS1115
- Author
-
Durelli, L., De Mercanti, S. F., Sormani, M. P., Piazza, F., Schiavetti, I., Gned, D., Brescia Morra, V., Lanzillo, R., Amato, L., Quarantelli, M., Ghezzi, A., Bianchi, A., Baroncini, D., Salemi, G., Realmuto, S., Ferrò, M. T., Vitetta, F., Superti, G., Cavalla, P., D’Onghia, M., Paolicelli, D., Pinessi, L., Trojano, M., and Clerico, M.
- Published
- 2014
10. Safety profile of Tysabri: international risk management plan
- Author
-
Iaffaldano, P., D’Onghia, M., and Trojano, Maria
- Published
- 2009
- Full Text
- View/download PDF
11. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment
- Author
-
Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Portaccio, E, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, A, Bergamaschi, R, Millefiorini, E, Clerico, Marinella, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Iaffaldano, P, Direnzo, V, D'Onghia, M, Lepore, V, Livrea, P, Comi, G, Amato, Mp, Italian Multiple Sclerosis Database Network Group, Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G., Tortorella, C., Simone, I., Patti, F., Ghezzi, A., Portaccio, E., Rossi, P., Pozzilli, C., Salemi, G., Lugaresi, A., Bergamaschi, R., Millefiorini, E., Clerico, M., Lus, Giacomo, Vianello, M., Avolio, C., Cavalla, P., Iaffaldano, P., Direnzo, V., D'Onghia, M., Lepore, V., Livrea, P., Comi, G., Amato, M., ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK, . ., Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP, M Trojano, F Pellegrini, D Paolicelli, A Fuiani, GB Zimatore, C Tortorella C, IL Simone, F Patti, A Ghezzi, E Portaccio, P Rossi, C Pozzilli, G Salemi, A Lugaresi, and on behalf of Italian Multiple Sclerosis Database Network (MSDN) group
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Propensity score ,Disease ,gender ,interferon beta ,multiple sclerosis ,observational study ,propensity score ,Lower risk ,Severity of Illness Index ,Multiple sclerosis, Interferon beta, Gender, Observational study, Propensity score ,Cohort Studies ,Disability Evaluation ,Young Adult ,Sex Factors ,gender, multiple sclerosis, treatment, interferon ,Double-Blind Method ,Internal medicine ,Observational study ,medicine ,Confidence Intervals ,Odds Ratio ,Product Surveillance, Postmarketing ,Humans ,Immunologic Factors ,Multiple sclerosi ,Proportional Hazards Models ,Expanded Disability Status Scale ,Proportional hazards model ,business.industry ,Multiple sclerosis ,Drug Administration Routes ,Interferon-beta ,medicine.disease ,Interferon beta ,Surgery ,Neurology ,Italy ,Cohort ,Propensity score matching ,Regression Analysis ,Settore MED/26 - Neurologia ,Female ,Neurology (clinical) ,business - Abstract
Background: There are a few and conflicting results from randomised controlled trials (RCTs) pertaining to the influence of gender in response to currently used disease modifying drugs in Multiple Sclerosis (MS). Observational studies may be especially valuable for answering effectiveness questions in subgroups not studied in RCTs. Objective: To conduct a post-marketing analysis aimed to evaluate the gender effect on Interferon beta (IFN beta) treatment response in a cohort of relapsing (RR) MS patients. Methods: A cohort of 2570 IFN beta-treated RRMS was prospectively followed for Lip to 7 years in 15 Italian MS Centers. Cox proportional hazards regression models were used to assess gender differences for risk of reaching 1st relapse and risk of progression by I point on Expanded Disability Status Scale (EDSS) score. Gender effects were also explored by a propensity score (PS) matching algorithm, and a tree-growing technique. Results: The multivariate Cox Regression analyses showed that male patients had a significant (p = 0.0097) lower risk for 1st relapse and a trend (p = 0.0897) for a higher risk to reach I point EDSS progression than females. The PS matched multivariate Cox Regression confirmed these results. The RECPAM analysis showed that male sex conferred a significant reduction in the risk for 1st relapse (HR = 0.86; 95% Cl = 0.76-0.98; p = 0.0226) in the subgroup with a low pre-treatment number of bouts, and a significant increase in the risk for I point EDSS progression (HR = 1.33; 95% Cl: 1.00-1.76; p
- Published
- 2009
12. Discontinuation of treatment with Natalizumab after 24 courses. Report from spontaneous, observational, prospective study (TYSTOP)
- Author
-
Clerico, M, De Mercanti, S, Piazza, F, Versino, E, Gned, D, Gibbin, M, Brescia Morra, V, Lanzillo, R, Amato, L, Quarantelli, M, Ghezzi, A, Bianchi, A, Baroncini, D, Ferrò, MT, Vitetta, F, D’Onghia, M, Paolicelli, D, Trojano, M, Durelli L., SALEMI, Giuseppe, REALMUTO, Sabrina, Clerico, M, De Mercanti, S, Piazza, F, Versino, E, Gned, D, Gibbin, M, Brescia Morra, V, Lanzillo, R, Amato, L, Quarantelli, M, Ghezzi, A, Bianchi, A, Baroncini, D, Salemi, G, Realmuto, S, Ferrò, MT, Vitetta, F, D’Onghia, M, Paolicelli, D, Trojano, M, and Durelli L
- Subjects
Multiple Sclerosis, Natalizumab, TySTOP ,Settore MED/26 - Neurologia - Published
- 2013
13. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis
- Author
-
Amato, M. P., Portaccio, E., Ghezzi, A., Hakiki, B., Zipoli, V., Martinelli, V., Moiola, L., Patti, F., La Mantia, L., Mancardi, G. L., Solaro, C., Tola, M. R., Pozzilli, C., De Giglio, L., Totaro, R., Lugaresi, A., Di Tommaso, V., Paolicelli, D., Marrosu, M. G., Comi, G., Pellegrini, F., Trojano, M., Siracusa, G., Rizzo, A., Zaffaroni, M., Radaelli, M., Milanese, C., Protti, A., Spreafico, C., Marazzi, R., Cavalla, P., Masera, S., Bergamaschi, R., Capello, E., Molinari, F., Caniatti, L., Granella, F., Immovilli, P., Annunziata, P., De Santi, L., Plewnia, K., Guidi, L., Bartolozzi, M. L., Mazzoni, M., De Luca, Giovanna, Carrozzo, A., D'Onghia, M., Musu, L., Cavallaro, T., Amato, M. P., Portaccio, E., Ghezzi, A., Hakiki, B., Zipoli, V., Martinelli, V., Moiola, L., Patti, F., La Mantia, L., Mancardi, G. L., Solaro, C., Tola, M. R., Pozzilli, C., De Giglio, L., Totaro, R., Lugaresi, A., Di Tommaso, V., Paolicelli, D., Marrosu, M. G., Comi, G., Pellegrini, F., Trojano, M., Siracusa, G., Rizzo, A., Zaffaroni, M., Radaelli, M., Milanese, C., Protti, A., Spreafico, C., Marazzi, R., Cavalla, P., Masera, S., Bergamaschi, R., Capello, E., Molinari, F., Caniatti, L., Granella, F., Immovilli, P., Annunziata, P., De Santi, L., Plewnia, K., Guidi, L., Bartolozzi, M. L., Mazzoni, M., De Luca, Giovanna, Carrozzo, A., D'Onghia, M., Musu, L., Cavallaro, T., and DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Fetal Disease ,Abortion ,Follow-Up Studie ,Cohort Studies ,Pregnancy ,Multiple Sclerosi ,medicine ,Abortion, Spontaneou ,Humans ,Prospective Studies ,Fetus ,treatment ,business.industry ,Obstetrics ,multiple sclerosis, treatment, pregnancy, interferon ,Infant, Newborn ,Pregnancy Outcome ,interferon ,Odds ratio ,Interferon-beta ,medicine.disease ,Confidence interval ,Surgery ,Abortion, Spontaneous ,Fetal Diseases ,Prospective Studie ,Fetal Weight ,In utero ,Propensity score matching ,Female ,Neurology (clinical) ,Cohort Studie ,business ,Cohort study ,Follow-Up Studies ,Human - Abstract
none 23 no Objective: To assess pregnancy and fetal outcomes after in utero exposure to interferon-beta (IFN beta) in all pregnancies occurring in women with multiple sclerosis (MS) during the study period, with a specific focus on the risk of spontaneous abortion. Methods: In this cohort study, data were gathered through a standardized, semi-structured interview. Patients who discontinued IFN beta less than 4 weeks from conception (exposed) were compared with those who had discontinued the drug at least 4 weeks from conception or who were never treated (not exposed). Possible confounders were handled through multivariate analyses adjusted for propensity score (PS). Results: We collected data on 396 pregnancies in 388 women, 88 classified as exposed (mean exposure 4.6 +/- 5.8 weeks). IFN beta exposure was not associated with an increased risk of spontaneous abortion (PS-adjusted odds ratio [OR] 1.08, 95% confidence interval [CI] 0.4 to 2.9, p = 0.88), although it was associated with both lower baby weight (PS-adjusted beta -113.8, p < 0.0001) and length (PS-adjusted beta -1.102, p < 0.0001). Proportion of spontaneous abortion in exposed patients fell within the range expected for the Italian population in the same period. IFN beta exposure (PS-adjusted OR 2.11, 95% CI 1.18 to 3.78, p = 0.012) and cesarean delivery were the only predictors of preterm delivery. In the exposed group, we did not observe any significant fetal complications, malformations, or developmental abnormalities over a median follow-up of 2.1 years. Conclusions: Our findings point to the relative safety of IFN beta exposure times of up to 4 weeks and can assist neurologists facing therapeutic decisions in women with MS with a pregnancy plan. Neurology (R) 2010;75:1794-1802 none Amato MP; Portaccio E; Ghezzi A; Hakiki B; Zipoli V; Martinelli V; Moiola L; Patti F; La Mantia L; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; Di Tommaso V; Paolicelli D; Marrosu MG; Comi G; Pellegrini F; Trojano M MS Study Group of the Italian Neurological Society; De Luca G Amato MP; Portaccio E; Ghezzi A; Hakiki B; Zipoli V; Martinelli V; Moiola L; Patti F; La Mantia L; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; Di Tommaso V; Paolicelli D; Marrosu MG; Comi G; Pellegrini F; Trojano M MS Study Group of the Italian Neurological Society; De Luca G
- Published
- 2010
14. post marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in intereron beta treatment
- Author
-
TROJANO M, PELLEGRINI F, PAOLICELLI D, FUIANI A, ZIMATORE GB, TORTORELLA C, SIMONE IL, PATTI F, GHEZZI A, PORTACCIO E, ROSSI P, POZZILLI C, SALEMI G, LUGARESI A, BERGAMASCHI R, MILLEFIORINI E, CLERICO M, LUS G, VIANELLO M, AVOLIO C, CAVALLA P, IAFFALDANO P, DIRENZO V, D'ONGHIA M, LEPORE V, LIVREA P, AMATO MP, ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK GROUP, COMI , GIANCARLO, Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Portaccio, E, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, A, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Iaffaldano, P, Direnzo, V, D'Onghia, M, Lepore, V, Livrea, P, Comi, Giancarlo, Amato, Mp, and ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK, Group
- Published
- 2009
15. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis
- Author
-
Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G., Tortorella, C., Simone, I., Patti, F., Ghezzi, A., Zipoli, V., Rossi, P., Pozzilli, C., Salemi, G., Lugaresi, A., Bergamaschi, R., Millefiorini, E., Clerico, M., Lus, G., Vianello, M., Avolio, C., Cavalla, P., Lepore, V., Livrea, P., Comi, G., Amato, M., Di Monte, E., Iaffaldano, P., Direnzo, V., D'Onghia, M., Lo Fermo, S., Messina, S., D'Amico, E., Rizzo, A., Zaffaroni, M., Portaccio, E., Martinelli, V., Prosperini, L., Onesti, E., Aridon, P., D'Amelio, M., Ragonese, P., De Luca, G., Farina, D., Di Tommaso, V., Tavazzi, E., Bargiggia, V., Crivelli, P., Cortese, A., Di Rezze, S., Durastanti, V., Alfieri, G., Rosellini, I., Modesto, M., Notariello, M., Tortorella, P., Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP, Di Monte E, Iaffaldano P, Direnzo V, D'Onghia M, Lo Fermo S, Messina S, D'Amico E, Rizzo A, Zaffaroni M, Portaccio E, Martinelli V, Prosperini L, Onesti E, Aridon P, D'Amelio M, Ragonese P, De Luca G, Farina D, Di Tommaso V, Tavazzi E, Bargiggia V, Crivelli P, Cortese A, Di Rezze S, Durastanti V, Alfieri G, Rosellini I, Modesto M, Notariello M, Tortorella P, Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Zipoli, V, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, Alessandra, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Lepore, V, Livrea, P, Comi, G, and Amato, Mp
- Subjects
Adult ,Male ,Time Factors ,Multiple Sclerosis ,Interferon beta ,Interferon-beta ,Cohort Studies ,Young Adult ,Multiple Sclerosis, Relapsing-Remitting ,Treatment Outcome ,observational study, multiple sclerosis, interferon, treatment, early ,Sickness Impact Profile ,Multiple Sclerosi ,Quality of Life ,Humans ,Female ,Settore MED/26 - Neurologia ,Prospective Studies ,Follow-Up Studies - Abstract
OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. delayed IFNbeta treatment on risk of reaching a 1-point progression in the Expanded Disability Status Scale (EDSS) score, and the EDSS 4.0 and 6.0 milestones. A set of PS-adjusted Cox hazards regression models were calculated according to different times of treatment initiation (within 1 year up to within 5 years from disease onset). A sensitivity analysis was performed to assess the robustness of findings. RESULTS: The lowest hazard ratios (HRs) for the three PS quintiles-adjusted models were obtained by a cutoff of treatment initiation within 1 year from disease onset. Early treatment significantly reduced the risk of reaching a 1-point progression in EDSS score (HR = 0.63; 95% CI = 0.48-0.85; p < 0.002), and the EDSS 4.0 milestone (HR = 0.56; 95% CI = 0.36-0.90; p = 0.015). Sensitivity analysis showed the bound of significance for unmeasured confounders. INTERPRETATION: Greater benefits on disability progression may be obtained by an early IFNbeta treatment in RRMS.
- Published
- 2009
16. Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study
- Author
-
Clerico, Marinella, DE MERCANTI, STEFANIA FEDERICA, Piazza, F., Virgilio, E., Gned, Dario, Brescia Morra, V., Lanzillo, Raffaella, Amato, Laura, Quarantelli, M., Ghezzi, A., Bianchi, A., Baroncini, D., Salemi, G., Realmuto, S., Ferrò, M. T., Vitetta, F., Superti, G., Cavalla, Paola, D'Onghia, M., Paolicelli, D., Schiavetti, I., Sormani, M. P., Pinessi, Lorenzo, Trojano, M., and Durelli, Luca
- Published
- 2014
17. How to treat MS patients after the 24 th natalizumab administration: the TY- STOP trial
- Author
-
Durelli, L., Mercanti, S. F., Sormani, M. P., Piazza, F., Schiavetti, I., Gned, D., Morra, V. Brescia, Lanzillo, R., Amato, L., Quarantelli, M., Ghezzi, A., Bianchi, A., Baroncini, D., Salemi, G., Realmuto, S., Ferro, M. T., Vitetta, F., Superti, G., Cavalla, P., D Onghia, M., Paolicelli, D., Pinessi, L., Trojano, M., and Marinella CLERICO
- Subjects
Multiple Sclerosis ,MRI - Published
- 2014
18. How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial
- Author
-
Durelli, L., Mercanti, S. F., Sormani, M. P., Piazza, F., Schiavetti, I., Gned, D., Morra, V. Brescia, Lanzillo, R., Amato, L., Quarantelli, M., Ghezzi, A., Bianchi, A., Baroncini, D., Salemi, G., Realmuto, S., Ferro, M. T., Vitetta, F., Superti, G., Cavalla, P., D Onghia, M., Paolicelli, D., Pinessi, L., Trojano, M., and Marinella CLERICO
- Subjects
Multiple Sclerosis ,Natalizumab ,MRI - Published
- 2014
19. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial
- Author
-
Edan, G, Comi, G, Le Page, E, Leray, E, Rocca, Ma, Filippi, M, French–Italian Mitoxantrone Interferon beta 1b Trial Group Trojano, M, Paolicelli, D, D'Onghia, M, Rumbach, L, Clavelou, P, Aufauvre, D, Moreau, T, Amato, Mp, Portaccio, E, Ghezzi, A, Mancardi, A, Vermersch, P, Hautecoeur, P, De Sèze, J, Magy, L, Vallat, Jm, Confavreux, C, Vukusic, S, Ionescu, I, Blanc, S, Pelletier, J, Malikova Klemina, I, Ranjeva, Jp, Debouverie, M, Pittion, S, Lebrun, C, Roullet, E, Heinzlef, O, Gout, O, Lubetzki, C, Stankoff, B, Tourbah, A, Veillard, D, Warter, Jm, Tranchant, C, Berry, I, Brassat, D, Clanet, M, Durelli, Luca, Clerico, Marinella, Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes], Université de Rennes (UR)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes = Institute of Clinical Neurosciences of Rennes (INCR), École des Hautes Études en Santé Publique [EHESP] (EHESP), Edan, G, Comi, Giancarlo, Le Page, E, Leray, E, Rocca, Ma, Filippi, Massimo, French Italian Mitoxantrone Interferon beta 1b Trial, Group, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes (INCR)
- Subjects
Oncology ,Male ,medicine.medical_treatment ,Gadolinium ,Severity of Illness Index ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Clinical endpoint ,030212 general & internal medicine ,10. No inequality ,Brain ,Immunosuppression ,Magnetic Resonance Imaging ,3. Good health ,Psychiatry and Mental health ,Methylprednisolone ,Drug Therapy, Combination ,Female ,Immunosuppressive Agents ,medicine.drug ,Interferon beta-1b ,Adult ,medicine.medical_specialty ,Multiple Sclerosis ,Neuroimaging ,Drug Administration Schedule ,03 medical and health sciences ,Multiple Sclerosis, Relapsing-Remitting ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,Mitoxantrone ,Expanded Disability Status Scale ,business.industry ,Multiple sclerosis ,Interferon-beta ,medicine.disease ,Surgery ,Secondary progressive ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
International audience; Objectives: The long-term impact of interferon-beta-1b (IFN) might be improved by short-term immunosuppression with mitoxantrone (MITOX) in aggressive relapsing-remitting multiple sclerosis (ARMS) patients. Methods: In this 3-year clinical and MRI study, 109 ARMS patients (two or more relapses in the previous 12 months and one or more gadolinium (Gd)-enhancing MRI lesion) were randomised into two groups: 54 patients received MITOX monthly (12 mg/m2; maximum 20 mg) combined with 1 g of methylprednisolone (MP) for 6 months followed by IFN for the last 27 months, and 55 patients received IFN for 3 years combined with 1 g of MP monthly for the first 6 months. The primary endpoint was the time to worsen by at least one Expanded Disability Status Scale point confirmed at 3 months. Results: The time to worsen by at least one Expanded Disability Status Scale point confirmed at 3 months was delayed by 18 months in the MITOX group compared with the IFN group (p
- Published
- 2011
20. Gender ratio of multiple sclerosis in Italy: geographical distribution and trend over 60 years
- Author
-
Lucchese, G, D'Onghia, M, Patti, Francesco, Pozzilli, C, Amato, M, Lugaresi, A, Ghezzi, A, Millefiorini, E, Marrosu, M, Salemi, G, Comi, G, Lus, G, Bergamaschi, R, Montanari, E, Giuliani, G, Vianello, M, Cogniglio, G, Cavalla, P, Granella, F, Rottoli, M, Granieri, E, Tedeschi, G, Avolio, C, Ardito, B, Gallo, P, Zorzon, M, DI BATTISTA, G, Ferrò, M, Scarpini, E, Sola, P, Carrieri, P, Graziano, G, Lepore, V, and Trojano, M.
- Published
- 2010
21. Real-life impact of early interferonβ therapy in relapsing multiple sclerosis
- Author
-
Trojano, M1, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Zipoli, V, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, A, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Lepore, V, Livrea, P, Comi, G, Amato, Mp, Italian Multiple Sclerosis Database Network (MSDN) Group, Di Monte, E, Iaffaldano, P, Direnzo, V, D'Onghia, M, Lo Fermo, S, Messina, S, D'Amico, E, Rizzo, A, Zaffaroni, M, Portaccio, E, Martinelli, V, Prosperini, L, Onesti, E, Aridon, P, D'Amelio, M, Ragonese, P, De Luca, G, Farina, D, Di Tommaso, V, Tavazzi, E, Bargiggia, V, Crivelli, P, Cortese, A, Di Rezze, S, Durastanti, V, Alfieri, G Rosellini I, Modesto, M, Notariello, M, and Tortorella, P.
- Published
- 2009
22. Integration among planning shapes and levels in the coastal areas management
- Author
-
Martinelli, Nicola, Lamacchia, M. R., and D'Onghia, M.
- Published
- 2007
23. ANALISI DELLE SITUAZIONI DI RISCHIO PER TIPOLOGIE DI PESCA SUI MOTOPESCHERECCI IN PROVINCIA DI BARI.
- Author
-
Falco, S., Giovine, Marta, Ammirabile, F., D’Onghia, M., Trani, G., Di Leone, G., Campo, G., Forte, Giulia, Pellicci, M., and De Merich, D.
- Subjects
- BARI (Italy)
- Published
- 2022
24. PND34 - The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta
- Author
-
Paolicelli, D, Iannazzo, S, Santoni, L, D’Onghia, M, Direnzo, V, Iaffaldano, A, Puma, E, Di Lecce, V, and Trojano, M
- Published
- 2015
- Full Text
- View/download PDF
25. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases
- Author
-
Francesco Ursini, Piero Ruscitti, Vincenzo Raimondo, Rossella De Angelis, Fabio Cacciapaglia, Erika Pigatto, Domenico Olivo, Ilenia Di Cola, Felice Galluccio, Francesca Francioso, Rosario Foti, Antonio Gaetano Tavoni, Salvatore D’Angelo, Corrado Campochiaro, Francesca Motta, Maria De Santis, Silvia Bilia, Caterina Bruno, Giacomo De Luca, Marcella Visentini, Jacopo Ciaffi, Luana Mancarella, Veronica Brusi, Martina D’Onghia, Giovanna Cuomo, Enrico Fusaro, Paola Cipriani, Lorenzo Dagna, Serena Guiducci, Riccardo Meliconi, Florenzo Iannone, Annamaria Iagnocco, Roberto Giacomelli, Clodoveo Ferri, Ursini, F., Ruscitti, P., Raimondo, V., De Angelis, R., Cacciapaglia, F., Pigatto, E., Olivo, D., Di Cola, I., Galluccio, F., Francioso, F., Foti, R., Tavoni, A. G., D'Angelo, S., Campochiaro, C., Motta, F., De Santis, M., Bilia, S., Bruno, C., De Luca, G., Visentini, M., Ciaffi, J., Mancarella, L., Brusi, V., D'Onghia, M., Cuomo, G., Fusaro, E., Cipriani, P., Dagna, L., Guiducci, S., Meliconi, R., Iannone, F., Iagnocco, A., Giacomelli, R., Ferri, C., DE LUCA, Giacomo, Ursini F., Ruscitti P., Raimondo V., De Angelis R., Cacciapaglia F., Pigatto E., Olivo D., Di Cola I., Galluccio F., Francioso F., Foti R., Tavoni A.G., D'Angelo S., Campochiaro C., Motta F., De Santis M., Bilia S., Bruno C., De Luca G., Visentini M., Ciaffi J., Mancarella L., Brusi V., D'Onghia M., Cuomo G., Fusaro E., Cipriani P., Dagna L., Guiducci S., Meliconi R., Iannone F., Iagnocco A., Giacomelli R., and Ferri C.
- Subjects
Rheumatology ,COVID-19 Vaccine ,Rheumatic Diseases ,COVID-19 ,Systemic rheumatic diseases, vasculitis, vaccination, COVID-19 ,General Medicine ,Immunotherapy ,Syndrome ,Letters of Biomedical and Clinical Research ,Human - Abstract
No abstract available
- Published
- 2022
26. Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases
- Author
-
Francesca Motta, Veronica Brusi, Corrado Campochiaro, Lorenzo Dagna, Enrico Fusaro, Ilenia Di Cola, Clodoveo Ferri, Fabio Cacciapaglia, Caterina Bruno, Rosario Foti, Riccardo Meliconi, Francesca Francioso, Felice Galluccio, Serena Guiducci, Vincenzo Raimondo, Jacopo Ciaffi, Annamaria Iagnocco, Giovanna Cuomo, Giacomo De Luca, Antonio Tavoni, Francesco Ursini, Roberto Giacomelli, Maria De Santis, Silvia Bilia, Piero Ruscitti, Salvatore D'Angelo, Florenzo Iannone, Domenico Olivo, Martina D'Onghia, Rossella De Angelis, Marcella Visentini, Luana Mancarella, E. Pigatto, Ursini, F., Ruscitti, P., Raimondo, V., De Angelis, R., Cacciapaglia, F., Pigatto, E., Olivo, D., Di Cola, I., Galluccio, F., Francioso, F., Foti, R., Tavoni, A., D'Angelo, S., Campochiaro, C., Motta, F., De Santis, M., Bilia, S., Bruno, C., DE LUCA, Giacomo, Visentini, M., Ciaffi, J., Mancarella, L., Brusi, V., D'Onghia, M., Cuomo, G., Fusaro, E., Dagna, L., Guiducci, S., Meliconi, R., Iannone, F., Iagnocco, A., Giacomelli, R., Ferri, C., Ursini, Francesco, Ruscitti, Piero, Raimondo, Vincenzo, De Angelis, Rossella, Cacciapaglia, Fabio, Pigatto, Erika, Olivo, Domenico, Di Cola, Ilenia, Galluccio, Felice, Francioso, Francesca, Foti, Rosario, Tavoni, Antonio, D'Angelo, Salvatore, Campochiaro, Corrado, Motta, Francesca, De Santis, Maria, Bilia, Silvia, Bruno, Caterina, De Luca, Giacomo, Visentini, Marcella, Ciaffi, Jacopo, Mancarella, Luana, Brusi, Veronica, D'Onghia, Martina, Cuomo, Giovanna, Fusaro, Enrico, Dagna, Lorenzo, Guiducci, Serena, Meliconi, Riccardo, Iannone, Florenzo, Iagnocco, Annamaria, Giacomelli, Roberto, Ferri, Clodoveo, Ursini, F, Ruscitti, P, Raimondo, V, De Angelis, R, Cacciapaglia, F, Pigatto, E, Olivo, D, Di Cola, I, Galluccio, F, Francioso, F, Foti, R, Tavoni, A, D'Angelo, S, Campochiaro, C, Motta, F, De Santis, M, Bilia, S, Bruno, C, De Luca, G, Visentini, M, Ciaffi, J, Mancarella, L, Brusi, V, D'Onghia, M, Cuomo, G, Fusaro, E, Dagna, L, Guiducci, S, Meliconi, R, Iannone, F, Iagnocco, A, Giacomelli, R, and Ferri, C
- Subjects
Male ,medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Immunology ,Population ,Arthritis ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,polymyalgia rheumatica ,Immune system ,Rheumatology ,Rheumatic Diseases ,Pandemic ,medicine ,Immunology and Allergy ,Humans ,Musculoskeletal Diseases ,Covid-19 ,arthritis ,vaccination ,Intensive care medicine ,Adverse effect ,education ,education.field_of_study ,business.industry ,SARS-CoV-2 ,COVID-19 ,Female ,Middle Aged ,medicine.disease ,Vaccination ,arthriti ,Molecular mimicry ,business - Abstract
In the past months, mass vaccination represented the turning point of the global battle against the COVID-19 pandemic, an unprecedented challenge for physicians, healthcare professionals, health systems and pharmaceutical companies. More than 6 billion doses of vaccine have been administered to date, covering nearly 50% of the world’s population. Although the vaccination campaign is still thwarted by spread of fake news disseminated by a ubiquitous antivaxxer movement, accumulating real-life data1 confirm the favourable safety profile already demonstrated in phase III clinical trials.2 Despite the lack of a steady literature evidence,3 the potential role of vaccines in promoting autoimmunity continues to intrigue many researchers. The theoretical basis of this association relies on the possible molecular mimicry between macromolecular components of the vaccine and specific human proteins and the exuberant immune response elicited by adjuvants contained in vaccines.4 Adverse events (AEs) associated with COVID-19 vaccines are usually mild and mainly restricted to injection site reactions. Interestingly, among systemic AEs, arthralgia is one of the most common.2 To the best of our knowledge, only isolated cases5 of arthritis developed after COVID-19 …
- Published
- 2022
27. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey
- Author
-
Micaela La Regina, Pasquale Viola, Riccardo Meliconi, Marco Miceli, Piero Ruscitti, Elena Borlandelli, Nicola Baldini, Lucia Lisi, Annamaria Iagnocco, Luana Mancarella, Jacopo Faranda Cordella, Cesare Faldini, Carlotta Cavallari, Veronica Brusi, Roberto De Giorgio, Claudio Borghi, Anna Mari, Francesco Ursini, Roberto Giacomelli, Martina D'Onghia, Maria Paola Landini, Jacopo Ciaffi, Alessandro Gasbarrini, and Ursini F, Ciaffi J, Mancarella L, Lisi L, Brusi V, Cavallari C, D'Onghia M, Mari A, Borlandelli E, Faranda Cordella J, La Regina M, Viola P, Ruscitti P, Miceli M, De Giorgio R, Baldini N, Borghi C, Gasbarrini A, Iagnocco A, Giacomelli R, Faldini C, Landini MP, Meliconi R
- Subjects
Male ,medicine.medical_specialty ,Fibromyalgia ,Coronavirus disease 2019 (COVID-19) ,Cross-sectional study ,Immunology ,Affect (psychology) ,Infections ,COVID-19 Testing ,Post-Acute COVID-19 Syndrome ,Rheumatology ,Internal medicine ,Surveys and Questionnaires ,Immunology and Allergy ,Medicine ,Humans ,COVID-19 ,fibromyalgia ,health services research ,Cross-Sectional Studies ,Female ,Internet ,SARS-CoV-2 ,United States ,business.industry ,Health services research ,medicine.disease ,Obesity ,Facet (psychology) ,business - Abstract
ObjectivePostacute COVID-19 syndrome (PACS) is an emerging entity characterised by a large array of manifestations, including musculoskeletal complaints, fatigue and cognitive or sleep disturbances. Since similar symptoms are present also in patients with fibromyalgia (FM), we decided to perform a web-based cross-sectional survey aimed at investigating the prevalence and predictors of FM in patients who recovered from COVID-19.MethodsData were anonymously collected between 5 and 18 April 2021. The collection form consisted of 28 questions gathering demographic information, features and duration of acute COVID-19, comorbid diseases, and other individual’s attributes such as height and weight. The American College of Rheumatology (ACR) Survey Criteria and the Italian version of the Fibromyalgia Impact Questionnaire completed the survey.ResultsA final sample of 616 individuals (77.4% women) filled the form 6±3 months after the COVID-19 diagnosis. Of these, 189 (30.7%) satisfied the ACR survey criteria for FM (56.6% women). A multivariate logistic regression model including demographic and clinical factors showed that male gender (OR: 9.95, 95% CI 6.02 to 16.43, pConclusionOur data suggest that clinical features of FM are common in patients who recovered from COVID-19 and that obesity and male gender affect the risk of developing post-COVID-19 FM.
- Published
- 2021
28. The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta.
- Author
-
Paolicelli, D, Iannazzo, S, Santoni, L, D’Onghia, M, Direnzo, V, Iaffaldano, A, Puma, E, Di Lecce, V, Trojano, M, and D'Onghia, M
- Subjects
- *
MULTIPLE sclerosis , *DISEASE relapse , *MEDICAL care costs , *IMMUNOGLOBULINS , *INTERFERONS , *PATIENTS - Published
- 2015
- Full Text
- View/download PDF
29. Chronobiology and chronotherapy in inflammatory joint diseases
- Author
-
Alfredo De Giorgi, Martina D'Onghia, Roberto Manfredini, Fabio Fabbian, Francesco Ursini, Roberto De Giorgio, Ursini F., De Giorgi A., D'onghia M., De Giorgio R., Fabbian F., and Manfredini R.
- Subjects
Chronotherapy ,Chronobiology ,business.industry ,medicine.medical_treatment ,Pharmaceutical Science ,Review ,medicine.disease ,Chronotherapy (treatment scheduling) ,Proinflammatory cytokine ,NO ,Polymyalgia rheumatica ,RS1-441 ,Pharmacy and materia medica ,chronobiology, inflammatory joint diseases, chronotherapy ,Prednisone ,Rheumatoid arthritis ,Immunology ,medicine ,LS7_3 ,Cytokine secretion ,Circadian rhythm ,business ,medicine.drug ,Inflammatory joint diseases - Abstract
Circadian rhythm perturbations can impact the evolution of different conditions, including autoimmune diseases. This narrative review summarizes the current understanding of circadian biology in inflammatory joint diseases and discusses the potential application of chronotherapy. Proinflammatory cytokines are key players in the development and progression of rheumatoid arthritis (RA), regulating cell survival/apoptosis, differentiation, and proliferation. The production and secretion of inflammatory cytokines show a dependence on the human day–night cycle, resulting in changing cytokine plasma levels over 24 h. Moreover, beyond the circadian rhythm of cytokine secretion, disturbances in timekeeping mechanisms have been proposed in RA. Taking into consideration chronotherapy concepts, modified-release (MR) prednisone tablets have been introduced to counteract the negative effects of night-time peaks of proinflammatory cytokines. Low-dose MR prednisone seems to be able to improve the course of RA, reduce morning stiffness and morning serum levels of IL-6, and induce significant clinical benefits. Additionally, methotrexate (MTX) chronotherapy has been reported to be associated with a significant improvement in RA activity score. Similar effects have been described for polymyalgia rheumatica and gout, although the available literature is still limited. Growing knowledge of chronobiology applied to inflammatory joint diseases could stimulate the development of new drug strategies to treat patients in accordance with biological rhythms and minimize side effects.
- Published
- 2021
30. Living with arthritis: a 'training camp' for coping with stressful events? A survey on resilience of arthritis patients following the COVID-19 pandemic
- Author
-
Francesco Ursini, Maria Paola Landini, Clodoveo Ferri, Martina D'Onghia, Veronica Brusi, Elisabetta Quaranta, Luana Mancarella, Jacopo Ciaffi, Amelia Spinella, Antonella Bruni, Dilia Giuggioli, Riccardo Meliconi, Lucia Lisi, Ciaffi J., Brusi V., Lisi L., Mancarella L., D'Onghia M., Quaranta E., Bruni A., Spinella A., Giuggioli D., Landini M.P., Ferri C., Meliconi R., and Ursini F.
- Subjects
Male ,Coping (psychology) ,Spondylarthropathie ,Inflammatory arthritis ,Arthritis ,Sex Factor ,Anxiety ,Arthritis, Rheumatoid ,Pandemic ,Adaptation, Psychological ,education.field_of_study ,Depression ,Brief Report ,General Medicine ,Middle Aged ,Resilience, Psychological ,Italy ,Female ,medicine.symptom ,Coronavirus Infections ,Case-Control Studie ,Arthriti ,Human ,Adult ,medicine.medical_specialty ,Population ,Pneumonia, Viral ,Betacoronavirus ,Sex Factors ,Rheumatology ,Internal medicine ,medicine ,Humans ,education ,Pandemics ,Aged ,Resilience ,Betacoronaviru ,business.industry ,SARS-CoV-2 ,Coronavirus Infection ,Arthritis, Psoriatic ,Case-control study ,COVID-19 ,medicine.disease ,Case-Control Studies ,Spondylarthropathies ,Stress, Psychological ,business - Abstract
Resilience is defined as “the capacity of individuals to cope successfully with significant change or adversity”. The challenge posed by the COVID-19 pandemic may potentially represent an overwhelmingly stressful event for patients with chronic diseases. Aim of our study was to investigate the levels of resilience in individuals with inflammatory arthritis living in Emilia Romagna, the third hardest-hit Italian region during the ongoing COVID-19 pandemic. To this purpose, we developed a survey consisting of four different sections assessing demographic characteristics, the 14-item resilience scale (RS14) and questionnaires evaluating depression and anxiety. Consecutive patients with inflammatory arthritis were recruited over a short time frame immediately after the end of national lockdown and compared with control individuals from the general population. One hundred twenty-two patients and 173 controls were included. Levels of resilience, as measured by RS14 score, were significantly higher in patients with inflammatory arthritis (82.6 ± 14.0 vs 79.0 ± 12.8, p = 0.018). After stratification for gender, the difference in RS14 score was maintained in women (p = 0.045), but not in men (p = 0.252). High resilience, defined as having a RS14 score > 90, was significantly more prevalent in patients than in controls (30% vs 16%, p = 0.009). In arthritis patients, no significant differences in RS14 were observed after stratification for specific diagnosis, age, or disease duration and activity. Our findings suggest that patients with inflammatory arthritis may be more resilient than the general population towards unexpected stressful events such as the ongoing COVID-19 pandemic.Key Points• Living with inflammatory arthritis may foster resilience.• After COVID-19, patients with inflammatory arthritis were more resilient than the general population. Electronic supplementary material The online version of this article (10.1007/s10067-020-05411-x) contains supplementary material, which is available to authorized users.
- Published
- 2020
- Full Text
- View/download PDF
31. Levels and Factors Associated with Resilience in Italian Healthcare Professionals during the COVID-19 Pandemic: A Web-Based Survey
- Author
-
Roberto De Giorgio, Agostino Chiaravalloti, Maria Paola Landini, Roberto Giacomelli, Elena Borlandelli, Francesco Ursini, Antonio Cimellaro, Lucia Lisi, Andrea D'Amuri, Luana Mancarella, Jacopo Ciaffi, Eugenio Garofalo, Piero Ruscitti, Giancarlo Facchini, Gaetano Gallo, Antonella Bruni, Pasquale Gramegna, Martina D'Onghia, Elisabetta Quaranta, Giacomo Caio, Micaela La Regina, Claudio Ripamonti, Luca Spinardi, Domenico Berardi, Veronica Brusi, Riccardo Meliconi, Pasquale Viola, Lisi L., Ciaffi J., Bruni A., Mancarella L., Brusi V., Gramegna P., Ripamonti C., Quaranta E., Borlandelli E., Gallo G., Garofalo E., Chiaravalloti A., Viola P., Ruscitti P., Caio G., D'Onghia M., D'Amuri A., Cimellaro A., Facchini G., Regina M.L., Spinardi L., de Giorgio R., Giacomelli R., Landini M.P., Berardi D., Meliconi R., and Ursini F.
- Subjects
Coronavirus disease 2019 (COVID-19) ,COVID-19 ,anxiety ,depression ,healthcare professionals ,resilience ,Population ,lcsh:BF1-990 ,education ,Development ,Article ,NO ,03 medical and health sciences ,Behavioral Neuroscience ,0302 clinical medicine ,Pandemic ,Genetics ,medicine ,030212 general & internal medicine ,Resilience (network) ,General Psychology ,Ecology, Evolution, Behavior and Systematics ,Depression (differential diagnoses) ,education.field_of_study ,business.industry ,healthcare professional ,Odds ratio ,lcsh:Psychology ,Anxiety ,medicine.symptom ,COVID-19, anxiety, depression, healthcare professionals, resilience ,business ,Body mass index ,030217 neurology & neurosurgery ,Demography - Abstract
Background: Resilience is defined as the capacity to cope successfully with change or adversity. The aims of our study were to investigate levels of resilience in Italian healthcare professionals (HCPs) during the Coronavirus disease 2019 (COVID-19) pandemic and to identify potential predictors of resilience. Methods: We performed a web-based survey of HCPs (n = 1009) working in Italian hospitals during the COVID-19 pandemic. The survey contained a 14-item resilience scale (RS14) and questionnaires to evaluate depression and anxiety symptoms. Non-HCP individuals (n = 375) from the general population were used for comparison. Results: HCPs showed significantly lower resilience compared to the control group (p = 0.001). No significant differences were observed after stratification for geographical area, work setting, role, or suspected/confirmed diagnosis of COVID-19. In a linear regression analysis, RS14 was inversely correlated with depression (R2 = 0.227, p <, 0.001) and anxiety (R2 = 0.117, p <, 0.001) and directly correlated with age (R2 = 0.012, p <, 0.001) but not with body mass index (BMI, R2 = 0.002, p = 0.213). In male HCPs, higher depression score (odds ratio (OR) 1.147, p <, 0.001) or BMI (OR 1.136, p = 0.011) significantly predicted having low resilience. In female HCPs, higher depression score (OR 1.111, p <, 0.0001) and working in a COVID-19 free setting (OR 2.308, p = 0.002) significantly predicted having low resilience. HCPs satisfied with personal protective equipment had higher levels of resilience (p <, 0.010). Conclusions: Our findings suggest that resilience was lower in Italian HCPs than in the general population after the first COVID-19 wave. Specific factors can be identified, and targeted interventions may have an important role to foster resilience of HCPs.
- Published
- 2020
32. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study
- Author
-
Paolo Ragonese, Simona Malucchi, Antonio Gallo, Mariangela D'Onghia, Viviana Nociti, Marta Radaelli, Valentina Tomassini, M. Rodegher, Giovanni Frisullo, Vincenzina Lo Re, Damiano Paolicelli, Pietro Annovazzi, Claudio Solaro, Massimiliano Calabrese, Claudio Gasperini, Carla Tortorella, Frisullo G, CM, Tortorella, C, Paolicelli, D, Ragonese, P, Annovazzi, P, Radaelli, M, Malucchi, S, Gallo, A, Tomassini, V, Nociti, V, D'Onghia, M, Lo Re, V, Rodegher, M, Solaro, C, Frisullo, G, Calabrese, M, Paolicelli, D, Gallo, Antonio, Gasperini, C., Frisullo, Giovanni, Calabrese, Massimiliano, Tortorella, Carla, Paolicelli, Damiano, Ragonese, Paolo, Annovazzi, Pietro, Radaelli, Marta, Malucchi, Simona, Tomassini, Valentina, Nociti, Viviana, D'Onghia, Mariangela, Lo Re, Vincenzina, Rodegher, Mariemma, Solaro, Claudio, and Gasperini, Claudio
- Subjects
Male ,Time Factors ,Thyroid Gland ,Autoimmunity ,Adverse effect ,medicine.disease_cause ,multiple sclerosis ,Gastroenterology ,thyroid ,Immunosuppressive Agent ,Risk Factors ,Retrospective Studie ,Prevalence ,interferon beta ,Thyroid ,adverse effects ,autoimmunity ,glatiramer acetate ,Middle Aged ,Treatment Outcome ,medicine.anatomical_structure ,Italy ,Neurology ,multiple sclerosi ,Thyroid autoimmunity ,Cohort ,Female ,Settore MED/26 - Neurologia ,Thyroid function ,Immunosuppressive Agents ,Interferon beta-1a ,Human ,Interferon beta-1b ,medicine.drug ,Adult ,medicine.medical_specialty ,Time Factor ,Thyroid Disease ,Risk Assessment ,Young Adult ,Multiple Sclerosis, Relapsing-Remitting ,Internal medicine ,medicine ,Humans ,Glatiramer acetate ,Retrospective Studies ,business.industry ,Risk Factor ,Multiple sclerosis ,Glatiramer Acetate ,medicine.disease ,Thyroid Diseases ,Immunology ,Neurology (clinical) ,business - Abstract
Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing-remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment. © The Author(s) 2014.
- Published
- 2014
33. Non-Invasive Imaging Including Line-Field Confocal Optical Coherence Tomography (LC-OCT) for Diagnosis of Cutaneous Lymphomas.
- Author
-
D'Onghia M, Mendonça-Sanches M, Erasti M, Cartocci A, Calabrese L, Sirchio A, Tognetti L, Batsikosta A, Lazzi S, Suppa M, Soglia S, Malvehy J, Perez-Anker J, Cencini E, Fabbri A, Rubegni P, and Cinotti E
- Abstract
Background/Objectives: Primary cutaneous lymphomas (PCL) are a heterogeneous group of non-Hodgkin lymphomas arising from malignant T (CTCL) or B (CBCL) cells, often mimicking other skin conditions. Recently, non-invasive diagnostic imaging modalities, including dermoscopy, Reflectance Confocal Microscopy (RCM), and Line-field Optical Coherence Tomography (LC-OCT), have become increasingly important, supporting clinicians in clinical practice. Hence, our study aimed to describe dermoscopic, RCM, and LC-OCT features of PCL and to explore their role in PCL management. Methods : Between December 2022 and January 2024, 40 lesions of 25 patients with PCL were retrospectively analyzed at the Dermatologic Unit of the University of Siena, Italy. Predefined dermoscopic, LC-OCT, and RCM criteria were assessed and their frequencies were calculated. Results: At dermoscopy, CTCL lesions were characterized by pinkish structureless areas (58,6%) and homogeneous distributed dotted vessels (35,7%), whereas 57.1% of CBCL presented with orange-yellow structureless areas. Considering CTCL, lymphocytes in the epidermis, dermal-epidermal junction, and dermis were detected by LC-OCT in 73.1%, 66.7%, and 51.9% and by RCM in 72.2%, 55.6%, and 61.1% of cases, respectively. The detection of lymphocytes was more precise using RCM than LC-OCT in CTCL ( p < 0.001). Dermal infiltration of medium-reflective cells was visible in 80% and 40% of CBCL cases by LC-OCT and RCM, respectively. Conclusions : Non-invasive imaging techniques may support clinicians in managing PCL; however, further studies are mandatory in this field.
- Published
- 2024
- Full Text
- View/download PDF
34. Evidence on Hidradenitis Suppurativa as an Autoinflammatory Skin Disease.
- Author
-
D'Onghia M, Malvaso D, Galluccio G, Antonelli F, Coscarella G, Rubegni P, Peris K, and Calabrese L
- Abstract
Hidradenitis suppurativa (HS) is a chronic and debilitating inflammatory skin disease that often exhibits heterogeneity in its clinical presentation, especially in the context of its rare syndromic forms. The pathogenesis of HS results from a complex interplay of genetic predisposition, innate and adaptive immunity dysregulation, smoking, obesity and environmental factors. In the early phase of the disease, the innate immune system is hyperactivated, contributing to tissue damage and triggering the activation and amplification of the adaptive immune response, which plays a pivotal role in the chronic stages of the disease. Recent studies focused on elucidating the importance of innate immunity impairment and autoinflammation in HS and increasing evidence has emerged on the occurrence of the disease in the context of well-known monogenic and polygenic autoinflammatory syndromes (AIDs). This review provides a comprehensive examination of the current scientific background supporting the contribution of autoinflammation to HS etiology, including genetic data, molecular studies and clinical evidence, as well as the association between HS and AIDs. However, further research is needed to shed light on the pathogenic mechanism of this challenging condition and to identify potential perspectives for future therapeutic approaches.
- Published
- 2024
- Full Text
- View/download PDF
35. Line-Field Confocal Optical Coherence Tomography: A New Skin Imaging Technique Reproducing a "Virtual Biopsy" with Evolving Clinical Applications in Dermatology.
- Author
-
Cappilli S, Paradisi A, Di Stefani A, Palmisano G, Pellegrino L, D'Onghia M, Ricci C, Tognetti L, Verzì AE, Rubegni P, Del Marmol V, Lacarrubba F, Cinotti E, Suppa M, and Peris K
- Abstract
Background: Line-field confocal optical coherence tomography is a novel technology able to reproduce a "virtual biopsy" of the skin. The aim of this review is to explore the application of line-field confocal optical coherence tomography (LC-OCT) in various skin diseases, covering skin cancers, inflammatory and infectious skin diseases, genetic diseases, cosmetic procedures, and less common disorders., Methods: Study selection was conducted based on LC-OCT and using pertinent MeSh terms, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines from inception to March 2024; to evaluate the quality and risk of bias of studies, Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was used., Results: the search retrieved 154 papers according to the selection criteria; after removing publications by one or more of the exclusion criteria, a total of 96 studies were found to be suitable for the analysis., Conclusions: Increasing evidence supports the use of LC-OCT as an adjunctive diagnostic tool for the in vivo diagnosis of a variety of skin tumors. As this device can be considered a "bridge" between dermoscopy and histopathology, widening applications in numerous fields of clinical dermatology, including inflammatory skin disease treatment, presurgical mapping, cosmetic procedures, and monitoring of non-invasive therapies, have been explored.
- Published
- 2024
- Full Text
- View/download PDF
36. Comparison of Ophthalmologists versus Dermatologists for the Diagnosis and Management of Periorbital Atypical Pigmented Skin Lesions.
- Author
-
Rubegni G, Zeppieri M, Tognetti L, Cinotti E, De Piano E, D'Onghia M, Orione M, Gagliano C, Bacci T, Tarantello A, Lo Russo N, Castellino N, Miranda G, Cartocci A, Tosi GM, and Avitabile T
- Abstract
Background/Objectives: Lentigo maligna (LM) and lentigo maligna melanoma (LMM) are significant subtypes of melanoma, with an annual incidence of 1.37 per 100,000 people in the U.S. These skin tumors, often found in photo-exposed areas such as the face, are frequently misdiagnosed, leading to delayed treatment or unnecessary excisions, especially in the elderly. Facial melanocytic skin tumors (lentigo maligna-LM/lentigo maligna melanoma-LMM) and their simulators (solar lentigo, pigmented actinic keratosis, seborrheic keratosis and lichen planus-like keratosis) often affect the periocular region. Thus, their diagnosis and management can involve different medical figures, mainly dermatologists and ophthalmologists. This study aimed to evaluate the ability of ophthalmologists to diagnose and manage pigmented skin lesions of the periorbital area. Methods : A multicentric, retrospective, cross-sectional study on a dataset of 79 periorbital pigmented skin lesions with both clinical and dermoscopic images was selected. The images were reviewed by six ophthalmologists and two dermatologists. Descriptive statistics were carried out, and the accuracy, sensitivity, and specificity, with their 95% confidence interval (95% CI), were estimated. Results: Ophthalmologists achieved a diagnostic accuracy of 63.50% (95% CI: 58.99-67.85%), while dermatologists achieved 66.50% (95% CI: 58.5-73.8). The sensitivity was lower for ophthalmologists in respect to dermatologists, 33.3% vs. 46.9%, respectively. Concerning the case difficulty rating, ophthalmologists rated as "difficult" 84% of cases, while for dermatologists, it was about 30%. Management was also consistently different, with a "biopsy" decision being suggested in 25.5% of malignant lesions by ophthalmologists compared with 50% of dermatologists. Conclusions: Ophthalmologists revealed a good diagnostic potential in the identification of periorbital LMs/LMMs. Given progressive population ageing and the parallel increase in facial/periorbital skin tumors, the opportunity to train new generations of ophthalmologists in the early diagnosis of these neoformations should be considered in the next future, also taking into account the surgical difficulty/complexity of this peculiar facial area.
- Published
- 2024
- Full Text
- View/download PDF
37. Fibromyalgia and Skin Disorders: A Systematic Review.
- Author
-
D'Onghia M, Ciaffi J, Calabrese L, Tognetti L, Cinotti E, Rubegni P, Frediani B, and Ursini F
- Abstract
Background: Fibromyalgia is a complex multifaceted syndrome primarily characterised by chronic musculoskeletal pain, fatigue, and functional symptoms. Although FM is known to be associated with several comorbidities, the aim of this systematic review was to comprehensively examine the available evidence regarding the relationship between FM and dermatological manifestations. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and MedLine and Web of Science (WOS) databases were searched up to June 2023. After removing duplicate records, 21 articles were deemed eligible for inclusion in the qualitative synthesis. Results: Overall, the included studies revealed an increased frequency of FM among patients with cutaneous diseases, including psoriasis, chronic urticaria, contact allergy, acneiform disorders, hidradenitis suppurativa, and vitiligo. Additionally, the presence of comorbid FM may intensify skin conditions, which has a negative impact on quality of life and vice versa. Conclusions: Although the causal mechanisms of FM are still far from being understood, this systematic review suggests a relationship between FM and skin disorders. However, further research is encouraged in this area.
- Published
- 2024
- Full Text
- View/download PDF
38. Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
- Author
-
Calabrese L, D'Onghia M, Lazzeri L, Rubegni G, and Cinotti E
- Abstract
Atopic dermatitis (AD) is an immune-mediated skin disorder with a chronic-relapsing course and a multifactorial pathogenesis. In contrast to the traditional concept of AD as solely a type 2 immune-activated disease, new findings highlight the disease as highly heterogeneous, as it can be classified into variable phenotypes based on clinical/epidemiological or molecular parameters. For many years, the only therapeutic option for moderate-severe AD was traditional immunosuppressive drugs. Recently, the area of systemic therapy of AD has significantly flourished, and many new substances are now marketed, licensed, or in the last step of clinical development. Biological agents and small molecules have enriched the therapeutic armamentarium of moderate-to-severe AD, such as dupilumab, tralokinumab, lebrikizumab (monoclonal antibodies targeting the IL-4/13 pathway), abrocitinib, upadacitinib, and baricitinib (JAK inhibitors). Indeed, the AD treatment paradigm is now split into two main approaches: targeting the IL-4/13 axis or the JAK/STAT pathway. Both approaches are valid and have strong evidence of preclinical and clinical efficacy. Therefore, the choice between the two can often be difficult and represents a major challenge for dermatologists. Indeed, several important factors must be taken into account, such as the heterogeneity of AD and its classification in phenotypes, patients' comorbidities, age, and personal preferences. The aim of our review is to provide an overview of the clinical and molecular heterogeneities of AD and to explore the factors and parameters that, in clinical practice, may help inform clinical decision-making.
- Published
- 2024
- Full Text
- View/download PDF
39. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition.
- Author
-
Dragotto M, D'Onghia M, Trovato E, Tognetti L, Rubegni P, and Calabrese L
- Abstract
Psoriasis is an inflammatory skin disease with a chronic relapsing course and an often-detrimental impact on patients' quality of life. Thanks to incredible advances in research over the past few decades, the therapeutic armamentarium of psoriasis is now reasonably broad and structured, with several therapeutic agents that have demonstrated successful long-term control of this condition. However, there are still unfulfilled gaps resulting from the inherent limitations of existing therapies, which have paved the way for the identification of new therapeutic strategies or the improvement of existing ones. A great deal of attention has recently been paid to the JAK/STAT pathway, playing a crucial role in chronic inflammatory skin diseases, including psoriasis. Indeed, in a disease with such a complex pathogenesis, the possibility to antagonize multiple molecular pathways via JAK/STAT inhibition offers an undeniable therapeutic advantage. However, data from clinical trials evaluating the use of oral JAK inhibitors in immune-mediated disorders, such as RA, have arisen safety concerns, suggesting a potentially increased risk of class-specific AEs such as infections, venous thromboembolism, and malignancies. New molecules are currently under investigation for the treatment of psoriasis, such as deucravacitinib, an oral selective inhibitor that binds to the regulatory domain of TYK2, brepocitinib (PF-06700841) and PF-06826647 that bind to the active site in the catalytic domain. Due to the selective TYK2 blockade allowing the inhibition of key cytokine-mediated signals, such as those induced by IL-12 and IL-23, anti-TYK2 agents appear to be very promising as the safety profile seems to be superior compared with pan-JAK inhibitors. The aim of our review is to thoroughly explore the rationale behind the usage of JAK inhibitors in PsO, their efficacy and safety profiles, with a special focus on oral TYK2 inhibitors, as well as to provide a forward-looking update on novel therapeutic strategies targeting the TYK2 pathway in psoriasis.
- Published
- 2024
- Full Text
- View/download PDF
40. Understanding the Dermoscopic Patterns of Basal Cell Carcinoma Using Line-Field Confocal Tomography.
- Author
-
Barbarossa L, D'Onghia M, Cartocci A, Suppa M, Tognetti L, Cappilli S, Peris K, Perez-Anker J, Malvehy J, Baldino G, Militello C, Perrot JL, Rubegni P, and Cinotti E
- Subjects
- Humans, Aged, Male, Female, Retrospective Studies, Middle Aged, Aged, 80 and over, Italy, Adult, Carcinoma, Basal Cell diagnostic imaging, Carcinoma, Basal Cell pathology, Dermoscopy methods, Skin Neoplasms diagnostic imaging, Skin Neoplasms pathology, Tomography, Optical Coherence methods
- Abstract
Basal cell carcinoma (BCC) is the most frequent malignancy in the general population. To date, dermoscopy is considered a key tool for the diagnosis of BCC; nevertheless, line-field confocal optical coherence tomography (LC-OCT), a new non-invasive optical technique, has become increasingly important in clinical practice, allowing for in vivo imaging at cellular resolution. The present study aimed to investigate the possible correlation between the dermoscopic features of BCC and their LC-OCT counterparts. In total, 100 histopathologically confirmed BCC cases were collected at the Dermatologic Clinic of the University of Siena, Italy. Predefined dermoscopic and LC-OCT criteria were retrospectively evaluated, and their frequencies were calculated. The mean (SD) age of our cohort was 65.46 (13.36) years. Overall, BCC lesions were mainly located on the head (49%), and they were predominantly dermoscopically pigmented (59%). Interestingly, all dermoscopic features considered had a statistically significant agreement with the LC-OCT criteria (all p < 0.05). In conclusion, our results showed that dermoscopic patterns may be associated with LC-OCT findings, potentially increasing accuracy in BCC diagnosis. However, further studies are needed in this field., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
41. Psoriasis and Fibromyalgia: A Systematic Review.
- Author
-
D'Onghia M, Ursini F, Cinotti E, Calabrese L, Tognetti L, Cartocci A, Lazzeri L, Frediani B, Rubegni P, and Trovato E
- Abstract
Psoriasis is a chronic inflammatory cutaneous condition characterized by several comorbidities, including musculoskeletal disorders. While the association with psoriatic arthritis has been widely addressed in literature, the aim of the present systematic review was to identify all available evidence on the relationship between psoriasis and fibromyalgia, a musculoskeletal syndrome primarily characterized by chronic widespread pain. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and MedLine and Web of Science (WOS) databases were searched for literature up to March 2023. After the removal of duplicate records, a total of 11 articles were deemed eligible for inclusion in a qualitative synthesis. Our results suggested that psoriatic patients had a higher prevalence of fibromyalgia (8-30%), with a very high impact on symptoms of psoriasis. Moreover, fibromyalgic patients had a slightly increased prevalence of psoriasis (2.2-6.7%) compared to the control groups. Finally, several studies demonstrated the substantial impact of fibromyalgia on psoriatic outcome measures in patients with concomitant psoriatic arthritis. In conclusion, available data support a potential interplay between psoriasis and fibromyalgia, but further research is encouraged in this area.
- Published
- 2024
- Full Text
- View/download PDF
42. Dermoscopy of atypical pigmented lesions of the face: Variation according to facial areas.
- Author
-
Tognetti L, Cartocci A, Cinotti E, D'Onghia M, Żychowska M, Moscarella E, Dika E, Farnetani F, Guida S, Paoli J, Lallas A, Tiodorovic D, Stanganelli I, Longo C, Suppa M, Zalaudek I, Argenziano G, Perrot JL, Rubegni G, Cataldo G, and Rubegni P
- Subjects
- Humans, Male, Female, Dermoscopy, Keratins, Diagnosis, Differential, Hutchinson's Melanotic Freckle diagnostic imaging, Hutchinson's Melanotic Freckle pathology, Skin Neoplasms pathology, Lentigo, Keratosis, Actinic diagnosis, Pigmentation Disorders
- Abstract
Atypical pigmented facial lesions (aPFLs)-including lentigo maligna (LM) and lentigo maligna melanoma (LMM), solar lentigo (SL), pigmented actinic keratosis (PAK), atypical nevi (AN), seborrheic keratosis (SK) and lichen planus-like keratosis (LPLK)-can exhibit clinical and dermoscopic overlapping features. We aimed to investigate if and how 14 dermoscopic features suggestive for the aforementioned aPFLs vary according to six facial sites among 1197 aPFLs cases (excised to rule out malignancy) along with lesion and patients' metadata. According to distribution and association analysis, aPFLs on the forehead of a male patient aged > 69 years displaying the obliterated follicular openings pattern, appear to be more at risk of malignancy. Of converse, aPFLs of the orbital/cheek/nose area with evident and regular follicular openings with diameter < 10 mm in a female aged below 68 are probably benign. The obliterated follicular openings, keratin plugs, evident and regular follicular openings and target-like pattern features differed significantly among six facial areas in all aPFLs cases. Lesion of the nose may show both features suggestive of malignancy and benignity (e.g. many SL and PAK may display target-like pattern and some LM/LMM cases display keratin plugs and evident and follicular openings), making these features less specific., (© 2023 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
43. Characteristics of Primary Cutaneous Lymphoma in Italy: A Tertiary Care, Single-Center Study.
- Author
-
D'Onghia M, Cartocci A, Calabrese L, Maio D, Sirchio A, Erasti M, Tognetti L, Rubegni P, Bocchia M, Cencini E, Fabbri A, and Cinotti E
- Subjects
- Humans, Aged, Tertiary Healthcare, Retrospective Studies, Mycosis Fungoides pathology, Lymphoma, T-Cell, Cutaneous pathology, Skin Neoplasms therapy, Skin Neoplasms pathology, Lymphoma, B-Cell pathology, Lymphoma, B-Cell therapy
- Abstract
Data on primary cutaneous lymphomas (PCLs) patients in the Italian population are limited, and, despite the existence of several treatment options, the management of those patients remains challenging. Our study aimed to investigate the clinical and therapeutic features of PCL patients in a referral center in Italy. We conducted a retrospective study on 100 consecutive PCL patients between January 2017 and December 2022. The mean (SD) age of our cohort was 70.33 (14.14) years. Cutaneous T-cell lymphomas (CTCLs) represented 65% of all cases; the majority were mycosis fungoides (42%), followed by cases of Sezary syndrome (10%) and primary cutaneous anaplastic large cell lymphoma (4%). Cutaneous B-cell lymphomas (CBCLs) accounted for 35 % of PCLs, with 15 cases of primary cutaneous follicle center lymphoma, 10 cases of primary cutaneous diffuse large B-cell lymphoma leg type, and 9 cases of marginal zone B-cell lymphoma. A higher frequency of pruritus ( p = 0.008) and higher peripheral blood levels of beta-2 microglobulin ( p ≤ 0.001) and lactate dehydrogenase ( p = 0.025) were found in CTCLs compared to those of CBCLs. Considering all therapeutic lines performed, treatments were extremely heterogeneous and skin-directed therapies represented the most frequently used approach. Our study confirms the distribution of PCL subtypes formerly reported in the literature and highlights the utility of real-life data in treatments to improve the current management of PCL patients.
- Published
- 2023
- Full Text
- View/download PDF
44. Unfolding dermatologic spectrum of Behçet's disease in Italy: real-life data from the International AIDA Network Behçet's disease Registry.
- Author
-
D'Onghia M, Cinotti E, Cartocci A, Vitale A, Caggiano V, Tognetti L, La Marca F, Sota J, Gentileschi S, Rubegni G, Lopalco G, Guerriero S, Govoni M, Monti S, Ruscitti P, Angeli F, Carubbi F, Giacomelli R, Ciccia F, Piga M, Emmi G, Costi S, Sebastiani GD, Iannone F, Spedicato V, Alessio G, Ruffilli F, Milanesi A, Gentile M, Crisafulli F, Alunno A, Navarini L, Iacono D, Cauli A, Ricci F, Gaggiano C, Tarsia M, Bartoloni E, Conti G, Viapiana O, Gobbi FL, de Paulis A, Parronchi P, Del Giudice E, Barone P, Olivieri AN, Bizzi E, Maggio MC, Balistreri A, Frediani B, Tosi GM, Fabiani C, Rubegni P, and Cantarini L
- Subjects
- Humans, Retrospective Studies, Prospective Studies, Italy epidemiology, Registries, Behcet Syndrome complications, Behcet Syndrome epidemiology, Behcet Syndrome diagnosis, Oral Ulcer epidemiology
- Abstract
Behçet's disease (BD) is a heterogeneous multifactorial autoinflammatory disease characterized by a plethora of clinical manifestations. Cutaneous lesions are considered hallmarks of the disease. However, their evolution over time and a thorough description are scarcely reported in non-endemic regions. The aim of this study was to detail BD skin manifestations and their evolution over time in Italy, as well as the dermatological prognostic impact of specific cutaneous features in long-standing disease. Data were collected in a double fashion, both retrospectively and prospectively, from the AutoInflammatory Disease Alliance (AIDA) international registry dedicated to BD, between January 2022 and December 2022. A total of 458 Italian patients were included. When assessing skin manifestations course, the constant or sporadic presence or absence of cutaneous involvement between onset and follow-up was considered. Oral ulcers (OU) (88.4%) and genital ulcers (GU) (52.6%), followed by skin involvement (53.7%) represented the most common presenting mucocutaneous manifestations at disease onset. Up to the time of enrolment into the AIDA registry, 411 (93.8%) patients had suffered from OU and 252 (57.9%) from GU; pseudofolliculitis (PF) accounted for the most common skin manifestation (170 patients, 37.1%), followed by erythema nodosum (EN) (102 patients, 22.3%), skin ulcers (9 patients, 2%) and pyoderma gangrenosum (4 patients, 0.9%). A prospective follow-up visit was reported in 261/458 patients; 24/148 (16.2%) subjects with skin involvement as early as BD onset maintained cutaneous lesions for the entire period of observation, while 120 (44.1%) patients suffered from sporadic skin involvement. Conversely, 94/113 (83.2%) with no skin involvement at disease onset did not develop skin lesions thereafter. At follow-up visits, cutaneous involvement was observed in 52 (20%) patients, with a statistically significant association between PF and constant skin involvement (p = 0.031). BD in Italy is characterized by a wide spectrum of clinical presentations and skin manifestations in line with what is described in endemic countries. Patients with skin disease at the onset are likely to present persistent cutaneous involvement thereafter; mucocutaneous lesions observed at the onset, especially PF, could represent a warning sign for future persistent skin involvement requiring closer dermatological care., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
45. Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome.
- Author
-
Giambruno R, Zacco E, Ugolini C, Vandelli A, Mulroney L, D'Onghia M, Giuliani B, Criscuolo E, Castelli M, Clementi N, Clementi M, Mancini N, Bonaldi T, Gustincich S, Leonardi T, Tartaglia GG, and Nicassio F
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive single-stranded RNA virus, engages in complex interactions with host cell proteins throughout its life cycle. While these interactions enable the host to recognize and inhibit viral replication, they also facilitate essential viral processes such as transcription, translation, and replication. Many aspects of these virus-host interactions remain poorly understood. Here, we employed the cat RAPID algorithm and utilized the RNA-protein interaction detection coupled with mass spectrometry technology to predict and validate the host proteins that specifically bind to the highly structured 5' and 3' terminal regions of the SARS-CoV-2 RNA. Among the interactions identified, we prioritized pseudouridine synthase PUS7, which binds to both ends of the viral RNA. Using nanopore direct RNA sequencing, we discovered that the viral RNA undergoes extensive post-transcriptional modifications. Modified consensus regions for PUS7 were identified at both terminal regions of the SARS-CoV-2 RNA, including one in the viral transcription regulatory sequence leader. Collectively, our findings offer insights into host protein interactions with the SARS-CoV-2 UTRs and highlight the likely significance of pseudouridine synthases and other post-transcriptional modifications in the viral life cycle. This new knowledge enhances our understanding of virus-host dynamics and could inform the development of targeted therapeutic strategies., Competing Interests: L.M. has received financial support from ONT for travel and accommodations to attend and present at ONT events. T.L. is a paid consultant to STORM therapeutics limited. This research was conducted in the absence of any commercial or financial relationships., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
46. Pso-Reg: a web registry for psoriasis in real life.
- Author
-
Trovato E, Cartocci A, Calabrese L, D'Onghia M, Dragotto M, Capalbo E, Silvi G, Manzo Margiotta F, Pimpinelli N, Pellegrino M, Romanelli M, Dini V, Cuccia A, Mazzatenta C, Rubegni P, and Prignano F
- Subjects
- Humans, Retrospective Studies, Comorbidity, Registries, Psoriasis therapy, Psoriasis drug therapy, Arthritis, Psoriatic drug therapy
- Abstract
Background: Psoriasis (PsO) is a common immune mediated inflammatory disease, affecting about 60 million people worldwide. Although current therapies have dramatically changed the therapeutic approach to the disease, the heterogeneity of responses often results in an essential unmet clinical need. This study describes the design and development of the Psoriasis Registry (Pso-Reg), an Italian electronic-based-registry, aimed to collect real life data of patients with psoriasis., Methods: Pso-Reg is a multicenter, retrospective and observational cohort study based on the Research Electronic Data Capture (REDcap) tool. Five Italian medical centres were part of the network and all patients affected by PsO were included in the study. Socio-demographic, clinical characteristics, laboratory findings and therapies were collected, and descriptive analysis was carried out., Results: Among the 768 patients analyzed, 446 were men (58.1%), with a mean age of 55.5 years. The first more frequent comorbidity was psoriatic arthritis (26.8%), followed by hypertension (25.3%), diabetes (10%) and dyslipidemia (11.7%). Of the entire cohort, 240 patients (38.2%) had a positive family history for PsO. Vulgar type was the most common phenotype (85.5%), with a major involvement of the scalp (13.8%). The mean PASI (Psoriasis Area Severity Index) score at the baseline was 7.5 (7.8). At the enrolment, 107 patients were treated with topic treatments (13.9%), 5 with phototherapy (0.7%), 92 with cDMARDs (conventional disease-modifying anti-rheumatic drugs) (12.0%) and 471 with biologic therapies (61.3%)., Conclusions: Real-life data from Pso-Reg could contribute providing the rationale for an individual-based strategy and a more tailored approach for the management of psoriasis.
- Published
- 2023
- Full Text
- View/download PDF
47. The economic burden of fibromyalgia: A systematic literature review.
- Author
-
D'Onghia M, Ciaffi J, Ruscitti P, Cipriani P, Giacomelli R, Ablin JN, and Ursini F
- Subjects
- Cost of Illness, Financial Stress, Health Care Costs, Humans, Quality of Life, Fibromyalgia therapy
- Abstract
Introduction: Fibromyalgia (FM) is a common disorder characterised by heterogeneous symptoms often leading to decreased functioning, work productivity and quality of life. Although a multimodal approach is used to treat FM, a significant proportion of patients show low satisfaction with perceived care, potentially resulting in an inefficient use of health care resources. The aim of the present review is to summarize the available evidence about the economic impact of FM and the specific cost drivers of health care expenditure for the syndrome., Methods: MedLine and Web of Science databases were searched to identify eligible articles. Studies reporting direct medical and non-medical costs and/or indirect costs of FM were included. Annual costs per person were extrapolated from each study and converted to United States Dollars ($) after adjusting the local currency for inflation in year 2019., Results: The 36 studies included in the final synthesis differed considerably in their design and in the cost categories analysed. Overall risk of bias was high. Estimates for the total annual direct costs per patient ranged from $ 1750 to $ 35,920 in the USA and from $ 1250 to $ 8504 in Europe. In most included studies, medications were the major contributor to overall expenditures., Conclusion: Fibromyalgia represents a substantial economic burden to health care systems and society. A better understanding of this complex disorder may not only improve quality of life of FM patients, but also have a significant impact on direct and indirect costs associated with the syndrome., Competing Interests: Declaration of Competing Interest None, (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
48. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases.
- Author
-
Ursini F, Ruscitti P, Raimondo V, De Angelis R, Cacciapaglia F, Pigatto E, Olivo D, Di Cola I, Galluccio F, Francioso F, Foti R, Tavoni AG, D'Angelo S, Campochiaro C, Motta F, De Santis M, Bilia S, Bruno C, De Luca G, Visentini M, Ciaffi J, Mancarella L, Brusi V, D'Onghia M, Cuomo G, Fusaro E, Cipriani P, Dagna L, Guiducci S, Meliconi R, Iannone F, Iagnocco A, Giacomelli R, and Ferri C
- Subjects
- COVID-19 Vaccines adverse effects, Humans, Immunotherapy, Syndrome, COVID-19 prevention & control, Rheumatic Diseases
- Published
- 2022
- Full Text
- View/download PDF
49. Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases.
- Author
-
Ursini F, Ruscitti P, Raimondo V, De Angelis R, Cacciapaglia F, Pigatto E, Olivo D, Di Cola I, Galluccio F, Francioso F, Foti R, Tavoni A, D'Angelo S, Campochiaro C, Motta F, De Santis M, Bilia S, Bruno C, De Luca G, Visentini M, Ciaffi J, Mancarella L, Brusi V, D'Onghia M, Cuomo G, Fusaro E, Dagna L, Guiducci S, Meliconi R, Iannone F, Iagnocco A, Giacomelli R, and Ferri C
- Subjects
- Female, Humans, Male, Middle Aged, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Musculoskeletal Diseases chemically induced, Rheumatic Diseases chemically induced, SARS-CoV-2 immunology
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2022
- Full Text
- View/download PDF
50. Histone Deacetylases as Modulators of the Crosstalk Between Skeletal Muscle and Other Organs.
- Author
-
Renzini A, D'Onghia M, Coletti D, and Moresi V
- Abstract
Skeletal muscle plays a major role in controlling body mass and metabolism: it is the most abundant tissue of the body and a major source of humoral factors; in addition, it is primarily responsible for glucose uptake and storage, as well as for protein metabolism. Muscle acts as a metabolic hub, in a crosstalk with other organs and tissues, such as the liver, the brain, and fat tissue. Cytokines, adipokines, and myokines are pivotal mediators of such crosstalk. Many of these circulating factors modulate histone deacetylase (HDAC) expression and/or activity. HDACs form a numerous family of enzymes, divided into four classes based on their homology to their orthologs in yeast. Eleven family members are considered classic HDACs, with a highly conserved deacetylase domain, and fall into Classes I, II, and IV, while class III members are named Sirtuins and are structurally and mechanistically distinct from the members of the other classes. HDACs are key regulators of skeletal muscle metabolism, both in physiological conditions and following metabolic stress, participating in the highly dynamic adaptative responses of the muscle to external stimuli. In turn, HDAC expression and activity are closely regulated by the metabolic demands of the skeletal muscle. For instance, NAD+ levels link Class III (Sirtuin) enzymatic activity to the energy status of the cell, and starvation or exercise affect Class II HDAC stability and intracellular localization. SUMOylation or phosphorylation of Class II HDACs are modulated by circulating factors, thus establishing a bidirectional link between HDAC activity and endocrine, paracrine, and autocrine factors. Indeed, besides being targets of adipo-myokines, HDACs affect the synthesis of myokines by skeletal muscle, altering the composition of the humoral milieu and ultimately contributing to the muscle functioning as an endocrine organ. In this review, we discuss recent findings on the interplay between HDACs and circulating factors, in relation to skeletal muscle metabolism and its adaptative response to energy demand. We believe that enhancing knowledge on the specific functions of HDACs may have clinical implications leading to the use of improved HDAC inhibitors for the treatment of metabolic syndromes or aging., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Renzini, D’Onghia, Coletti and Moresi.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.